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Pavan Reddy,1 Marcos de Lima,2 John Koreth3Despite improvements to hematopoietic stem cell transplantation over the past several decades, further
advances are necessary to achieve: improved control of toxicities like graft-versus-host disease; enhanced
immunologic reconstitution posttransplantation; and reduction in relapse risk via enhancement of graft-
versus-tumor responses. Achieving these disparate hematopoietic stem cell transplantation goals will likely
require the introduction of novel therapeutic agents to the current armamentarium. In this article, we outline
preclinical and early-phase clinical data indicating the potential of proteasome-inhibitor therapy (bortezo-
mib), hypomethylating agent therapy (azacytidine), and histone deacetylase-inhibitor therapy (vorinostat)
to help improve hematopoietic stem cell transplantation outcomes.
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Advances in donor selection and supportive care
have improved allogeneic hematopoietic stem cell
transplantation (HSCT) outcomes over the past several
decades. However, major challenges remain, in partic-
ular, ameliorating graft-versus-host disease (GVHD)
and reducing disease relapse posttransplantation. In
this article, we summarize efforts to intercalate novel
therapeutic agents into HSCT to help improve its effi-
cacy and tolerability. We focus here on three classes of
agents: proteasome inhibition (bortezomib), DNA
hypomethylating therapy (azacytidine), and histone
deacetylase inhibition (vorinostat).SECTION I: PROTEASOME INHIBITION
AND HSCT
GVHD is a significant barrier to allogeneic HSCT
[1]. Ex vivo T cell depletion can prevent acute and
chronic GVHD (aGVHD, cGVHD) but is associated
with graft rejection, impaired immune reconstitution,1University of Michigan, Ann Arbor, Michigan; 2M.D.
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disease, and malignant relapse [2]. In reduced-
intensity conditioning (RIC) transplantation, primar-
ily dependent on immunologic graft-versus-tumor
(GVT) effect for cure, in vivo T cell antibody-based
therapy (eg, antithymocyte globulin) may also impair
survival [3]. Further, in T cell-replete RIC HSCT
utilizing standard calcineurin inhibitor-based prophy-
laxis, HLA mismatch is associated with a high GVHD
rate and impaired survival [4]. Novel GVHD
approaches are necessary.
Bortezomib is a proteasome inhibitor effective
against multiple myeloma via inhibition of nuclear
factor-kB (NF-kB), attenuation of interleukin-6-
mediated cell growth, a direct apoptotic effect, andpos-
sibly antiangiogenic and other mechanisms [5]. In the
immunologic context, NF-kB has important roles in
cytokine signaling and T cell activation, proliferation,
and apoptosis [6-9]. Bortezomib inhibits antigen-
presenting cells by attenuation of Toll-like-receptor-
4-mediated activation and endoplasmic reticulum
homeostasis, with reduced cytokine production and
immunostimulatory activity [10,11]. In preclinical
studies, bortezomib preferentially and specifically
depleted alloreactive T-lymphocytes [12]. In mouse
models of HLA-mismatchedHSCT, early bortezomib
administration protected against aGVHD without
impairing engraftment or GVT responses [13-15].
Indeed, bortezomib could enhance the GVT
response. In addition to direct tumor cytotoxicity, bor-
tezomib can sensitize target cells to immune-mediated
killing through TRAIL/DR5 and Fas/FasL pathways
on natural killer (NK) and CD81 T effector cells
[16-21]. In general, studies indicate that bortezomibS125
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Fas andDR5, which, combinedwith downregulation of
antiapoptotic molecules, can promote cytotoxic C
lymphocyte and NK-mediated killing. In addition,
bortezomib downregulates major histocompatibility
complex I expression on tumor cell surfaces and
promotes their NK-mediated killing [17,22]. Further,
bortezomib cytotoxicity may increase tumor
immunogenicity via the cell surface expression of
heat-shock protein 90 [23]. Proteasome inhibition
with bortezomib therefore appears appealing inHSCT.
However, in a noteof caution, prolongedor delayed
bortezomib administration resulted in a GVHD-like
lethal toxicity of the gastrointestinal tract of trans-
planted animals [14,15]. This was associated with
a rise in the inflammatory cytokines interluekin
(IL)-1b, IL-6, and tumor necrosis fiactor (TNF)-a,
and an increase in intestinal TNFR1 expression [14].
This toxicity may be because of bortezomib effects
beyond inhibition of theNF-kB pathway, as prolonged
exposure to a more selective proteasome inhibitor,
PS-1145, did not result in such toxicity [15].
We undertook a prospective phase I/II trial to
evaluate a bortezomib-based regimen for GVHD con-
trol after 1 to 2 locus HLA-mismatched unrelated do-
nor RIC HSCT. The RIC regimen combined
fludarabine and busulfan, with GVHD prophylaxis
comprising tacrolimus, mini-methotrexate, and added
bortezomib. In phase I, 3 bortezomib dose levels (1,
1.3, and 1.5 mg/m2 i.v.) administered on days 11,
14, and 17 identified a maximum tolerated dose of
1.3mg/m2; with prompt engraftment, minimal toxicity
(eg, no neurotoxicity, colonic necrosis), and evidence
for improved aGVHD control [24]. In mature phase
I/II data, withmedian follow-up in survivors of 2 years,
the short-course bortezomib-based regimen had
demonstrable efficacy, with a grade II-IV aGVHD
rate in the range for HLA-matched transplantation,
as well as comparable survival (unpublished data).
We also documented preliminary evidence of im-
proved cGVHD control and enhanced CD81 T and
NK cell reconstitution with bortezomib compared
with sirolimus-based T cell-replete regimens. This ap-
pears promising, as prior T cell-replete aGVHD pro-
phylaxis regimens typically have not lowered cGVHD
incidence [25].
In contrast with the findings with short-course
bortezomib, toxicity was noted in a study evaluating
biweekly bortezomib dosed at 1.3 mg/m2 on days 1, 4,
8, and 11 every 21 days for two to four cycles in order
to improve myeloma-free survival in 18 patients with-
out evidence of relapsed or progressive disease after
allogeneic transplantation [26]. Eighteen patients
received bortezomib, ninewith concomitant cyclospor-
ine, and two received additional low-dose thalidomide.
Grade 3-4 toxicities included thrombocytopenia (50%),
leukopenia (17%), and neuropathy (17%). Significantneuropathy was observed with concomitant cyclospor-
ine (three versus zero;P5 .06).Of note, twopatients ex-
perienced mild progression of preexisting cGVHD of
the mouth or skin that did not require systemic immu-
nosuppressive therapy.
Prospective trials of proteasome inhibition for
GVHD prophylaxis in the myeloablative context,
and for therapy of steroid-refractory aGVHD, are cur-
rently ongoing. Similarly, in the cGVHD context,
there are ongoing prospective phase II clinical trials
evaluating the impact of bortezomib treatment for
newly diagnosed, and for steroid-refractory cGVHD.
The results of these studies are keenly awaited.
Another therapeutic approach combines bortezo-
mib with adoptive immunotherapy for enhanced
antitumor response. Bortezomib administration post-
allogeneic HSCT is predicated in part on the notion
of sensitizing residual tumor cells to killing by
donor-derived cytotoxic T and NK cells [18,27].
Adoptive therapy utilizing ex vivo IL-2-expanded
human autologous NK cells, with bortezomib-based
tumor presensitization, has been explored with efficacy
in in vitro and in vivo mouse tumor models
[17,18,21,28]. This strategy is being evaluated in
a phase I trial of escalating doses of adoptive ex vivo
expanded autologous NK cells in patients with
treatment-refractory solid tumors or hematologic
malignancies, that are sensitized to NK cell cytotoxic-
ity using bortezomib. The combined use of bortezo-
mib and donor NK infusions (with IL-2) are also
under investigation in a phase I/II trial as part of an
RIC preparative regimen of bortezomib, cyclophos-
phamide, fludarabine, antithymocyte globulin, and
total-body irradiation before haploidentical allogeneic
HSCT, for patients with myeloid leukemia or myelo-
dysplastic syndromes unsuitable for HLA-matched
myeloablative transplantation.
Proteasome inhibition appears a promising
approach for both GVHD prophylaxis and treatment
and may also offer improved GVT responses and
enhanced immune reconstitution.SECTION II: HYPOMETHYLATING AGENTS
AND HSCT
Azacitidine (AZA) is a pyrimidine nucleoside ana-
log of cytidine, believed to exert its antineoplastic
effects by causing hypomethylation of DNA and direct
cytotoxicity on abnormal hematopoietic cells. Hyper-
methylation of promoter regions is an importantmech-
anism of suppression of several genes putatively
involved in the control of growth of leukemic cells.
Methylation of CpG dinucleotide islands in human
DNA is maintained by the enzyme cytosine DNA
methyltransferase. The inhibition of this enzyme by
AZA or decitabine is associated with hypomethylation
and potentially with restoration of normal function to
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both AZA and decitabine, these actions appear to be
dose-dependent: higher doses are cytotoxic, whereas
hypomethylation occurs at lower doses [29,30]. AZA
is moderately effective in myelodysplastid syndromes
(MDS)/acute myelogeneous leukemia (AML) (outside
the HSCT setting), however, in doses that are likely
to induce severe pancytopenia after HSCT [31].
Several investigators have demonstrated since the
early 1980s that hypomethylating agents have in vitro
immunologic and cell-differentiating effects [32,33].
Exposure of myeloid leukemic blasts to these drugs
induces phenotypic modification including reduction
of CD13 and CD33 expression, increased antigenic
density of maturation surface determinants such as
CD16 and CD11c, and increased expression of major
histocompatibility complex-class I molecules, HLA-
DR, and beta-2-microglobulin. Recent publications
suggested that the expression of other cancer-
associated antigens could also be maximized, poten-
tially increasing susceptibility to immune-mediated
effects [34].
We hypothesized that low doses of AZA would be
well tolerated and potentially efficacious in treating
AML/MDS relapse after allogeneic HSCT [35]. Our
preliminary experience showed that doses in the range
of 16 to 40 mg/m2 for 5 days can induce remission and
restore full donor chimerism in 15% to 25% of
patients (mostly with indolent, low bulk disease).
The drug was administered outpatient and was associ-
ated with acceptable toxicities. Interestingly, several
patients appeared to achieve a state of ‘‘stable disease,’’
without the need for hospital admissions despite
disease relapse (unpublished personal observation).
These results highlighted the anti-AML/MDS
activity and tolerability of low-dose AZA in the alloge-
neic setting, and lead us to consider AZA to prevent
relapse. However, pharmacologic maintenance is diffi-
cult to achieve with traditional agents because of mul-
tiple drug interactions and myelosuppression risk. An
ideal drug should have activity against the disease,
without excessive myelosuppression when adminis-
tered repeatedly after transplant, and low-dose AZA
appeared to fit the required profile.
We conducted a phase I study (started in 2005)
aimed at defining AZA maximum-tolerated dose early
after HSCT (6th to 8th week).We assumed that recur-
rence prevention should start as early as possible, given
that relapses tend to occur early for patients trans-
planted off complete remission. The caveat is that
this is also a period of time in which the graft is very
sensitive to myelosuppression, and other comorbid
conditions may be active given the proximity with
the transplantation.We opted for a study to determine
a safe dose/schedule combination, which unlike classic
phase I studies, would also provide information re-
garding feasibility of administering AZA in multiplecycles (up to an arbitrarily defined limit of four rounds)
[36]. Using a Bayesian adaptive method to determine
the best dose/schedule combination based on time to
toxicity, we investigated combinations of one to four
cycles, and five doses (8, 16, 24, 32, and 40 mg/m2).
Forty-five high-risk patients with a median age of
60 years were treated. Dose-limiting toxicity was
reversible thrombocytopenia, and the optimal combi-
nation was 32 mg/m2/four cycles. We also observed
that the probability of developing cGVHD decreased
significantly with the number of AZA cycles but was
unaffected by dose. Given that we excluded patients
with uncontrolled GVHD and started treatment after
the HSCT 5th week, no firm conclusion regarding
aGVHD could be made. With a median follow-up of
20.5 months, 1-year event-free survival and overall
survival rates were 58% and 77% [37].
Platzbecker and collaborators [38] have taken
a different approach, using higher doses of AZA
(75 mg/m2/day for 7 days) as preemptive treatment
of hematologic recurrence. Patients experiencing
a decrease of CD341 donor chimerism were treated
to prevent or delay hematologic relapse. Treatment
was feasible, and a significant fraction of patients so
treated did not go to overt relapse, or had it delayed.
More recently, several groups have shownhypome-
thylating agent-induced, increased FOXP3 expression
and regulatory T-lymphocyte generation inmice. This
could theoretically suggest the risk of less GVT
effect—a risk that does not appear to be present in
our clinical trials [39,40]. Interestingly, our in-human
data indicate that low-dose AZA does indeed hypome-
thylate areas in the FOXP3 gene (such as amplicon 9,
which belongs to the FOXP3 coding region) (Simrit
Parmar, personal communication).
Currently, 69 patients with myeloid leukemias
(median age, 56 years; range, 20-73 years) have
received AZA for relapse prevention in our institution;
70% were not in complete remission at HSCT,
whereas 23% were treated after the second transplant.
Median follow-up is 27 months (range, 6-80 months).
A median of three cycles/per patient were adminis-
tered (range, 1-24) at 8 mg/m2-40 mg/m2. Thirty-
three patients have relapsed, five during therapy and
28 after maintenance was stopped. Overall survival
and event-free survival rates continue to compare
favorably with our historic data in similarly high-risk
populations. Chronic GVHD was diagnosed in 31 pa-
tients (44%), two of them while receiving AZA, and 29
at a median of 140 days after the drug was stopped.
This update confirms the safety of maintenance
therapy. There has been no graft loss, and chimerism
is either maintained or improved, and no drug-related
death has occurred. The ideal duration of treatment is
unknown, but survival after drug discontinuation was
improved in those patients that received more than
three cycles (6-month survival of 96% versus 79%,
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controlled validation but provide the basis for our
ongoing randomized trial comparing AZA given every
28 days for 1 year after HSCT, versus no maintenance.
Patients in remission after transplantation receive AZA
32 mg/m2 subcutaneously for 5 days, starting on day1
40-100 post-HSCT. Availability of an oral AZA formu-
lation may simplify this approach in the future.
In summary, our preliminary experience would
suggest that low-dose AZA given monthly might be
efficacious in preventing AML/MDS recurrence after
allogeneic transplantation.SECTION III: HISTONE DEACETYLASE
INHIBITION AND HSCT
Histones aremajor structural proteins that package
DNA into chromatin and play an important role in
gene regulation. DNA wraps around a histone
octamer composed of histones H2A, H2B, H3, and
H4 to form a nucleosome, and the histone H1 links
the octameric core into chromatin. Covalent modifica-
tion on the amino terminal of the core histones through
acetylation affect nuclear replication, chromatin
assembly, and transcription, and provide insight into
the epigenetic regulation of gene expression [41,42].
Histone acetylation is tightly regulated by the balance
between the enzymes histone acetyltransferases and
histone deacetylases (HDACs).
Histone acetyltransferases include more than
20 members of acetylate-specific lysine residues of the
histone components of chromatin,whereasHDACsde-
acetylate the lysine residues. HDACs comprise a family
of 18 genes subdivided into four distinct classes: class I
(HDAC1, 2, 3, and 8), class II (HDAC5, 6, 7, 9, and 10),
and class IV (HDAC 11) [43]. Much research on these
enzymes has focused on their ability to modulate acety-
lation of histones and the regulation of chromatin, al-
though emerging data demonstrate that HDACs can
also target nonhistone cellular proteins [43] and that
disruption in the balance of acetylation and deacetyla-
tion affects a broad range of human disorders.
HDAC inhibitors (HDACis) have emerged as an
important class of anticancer agents that inhibit the enzy-
matic activity of primarily class I and II HDACs with
varying efficiency thereby causing increasedhistone acet-
ylation and gene transcription. Suberoylanilide
hydroxamic acid—SAHA (vorinostat)—is a hydroxa-
mic-containing agent that was approved by the US
Food and Drug Administration for treatment of cutane-
ous T-cell lymphoma [44,45]. Although a large range of
different HDACis have been studied and developed for
cancer therapy, we and others have demonstrated that
HDACis at lower and noncytotoxic concentrations
possess a novel and potent anti-inflammatory and immu-
noregulatory effect [46,47].Emergingdata frommultiple
laboratories demonstrate that HDACis can suppressseveral inflammatory and immune-mediated diseases
such as lupus, sepsis, inflammatory bowel disease, rheu-
matoid arthritis, autoimmune diabetes, allograft toler-
ance, and GVHD in preclinical models [46-55].
Insights into the cellular and molecular pathogen-
esis of GVHD implicate proinflammatory cytokines
and host antigen-presenting cells, such as dendritic
cells (DCs), as important targets for reducing GVHD
[55,56]. Micromolar concentrations of SAHA are
required for antitumor effects, whereas nanomolar
concentrations of SAHA reduce the secretion of
inflammatory cytokines, such as TNF-a, interferon-
g, IL-1b, and IL-12. Given the anti-inflammatory
properties of these agents and based on the central
role of proinflammatory cytokines in the pathogenesis
of aGVHD,we investigated the role of SAHA in awell-
characterized murine model of allogeneic HSCT.
SAHA or ITF 2357 were administered during the
amplification of the proinflammatory cascade early in
the time course of transplant without interrupting
the initial donor T cell interaction with host antigen-
presenting cells. SAHA significantly reduced serum
levels of TNF-a, IL-1, and inteferon-g after allogenic
bone marrow transplantation [48]. Furthermore, this
reduction in the proinflammatory cytokines was asso-
ciated with a reduction in the GVHD mortality and
GVHD-specific target organ damage in multiple mu-
rine models.
We analyzed for the potential mechanisms and
focused on host-derived dendritic cells, because DCs
serve as the sentinels of the immune response and func-
tion as the most potent antigen-presenting cells [57].
Bone marrow-derived DCs treated with SAHA or
ITF 2357 and then stimulated with Toll-like receptor
agonists such as LPS, secreted significantly reduced
amounts of proinflammatory cytokines such as IL-1b,
TNF-a, IL-12, and IL-6 in a dose-dependent manner
[49]. Treatment of DCs with SAHA increased indole-
amine 2,3-dioxygenase (IDO), an immune-regulatory
enzyme, expression at the protein and mRNA levels.
Utilizing three complementary approaches:
siRNA, pharmacologic inhibition by 1-MT, and ge-
netically deficient IDO12/2 mice, we demonstrated
the importance of IDO induction in the DCs. We fur-
ther dissected the mechanism of IDO induction and
found that STAT-3 was critical for induction of IDO
after treatment with HDAC [58]. STAT-3 was acety-
lated following SAHA treatment of DCs.When the ef-
fect of SAHA was tested on the induction of IDO in
cell lines expressing STAT-3-deficient, wild-type,
and mutantK685R, HDAC-inhibition enhanced IDO
expression in the WT STAT-3 transfected cells but
not in the null control or the acetylation-resistant
STAT-3 mutantK685R.
Experimental data show that HDACi reduce mu-
rine GVHD and have a multitude of effects on im-
mune cells, reduce the secretion of inflammatory
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Given these preclinical observations and the good
therapeutic index of the oral preparations of SAHA,
a clinical trial has been launched at the University of
Michigan and Washington University to test the con-
cept that deacetylase inhibition, when used as an ad-
junct with standard CI prophylaxis will reduce the
incidence and severity of aGVHD after RIC in
matched-related donor allogeneic HSCT.
This trial is based on the institutional experience of
GVHDwith RIC regimens. Prior experience with this
approach showed a 42% incidence of grades II-IV
GVHD, with a 50% 2-year survival rate [59]. The trial
will evaluate whether adding HDACi, SAHA will
reduce the incidence of grade II-IV GVHD to 25%.
It is an open-label, nonrandomized, phase II clinical
trial using the same RIC regimen (fludarabine and
busulfan) that has been utilized for approximately
10 years at our institution. The GVHD prophylaxis
backbone consists of tacrolimus (day23 to day 56, fol-
lowed by a taper over 4 months) and mycophenolate
mofetil (day 0 to day 28). Vorinostat is currently being
administered orally from day 210 to day 1100 at
100 mg twice daily.
So far, 32 patients have been treated at 100-mg and
200-mg dose levels. Because 100 mg twice daily
induced acetylation in circulating peripheral blood
mononuclear cells and appeared better tolerated than
the 200-mg twice daily dose in the initial cohort of
patients, the study is being continued at the 100-mg
twice daily dose. Thus far, all patients in the trial
have engrafted successfully, and there have been no
dose-limiting toxicities. The rates of aGVHD remain
lower than historical controls at 22%. The data from
this trial will be discussed.
This is the first human study ofHDAC inhibition in
allogeneic bonemarrow transplantationpatients. If suc-
cessful, it could lead to the development of an entirely
new class of immune-modulatory therapy for GVHD
and perhaps for immune/inflammatory diseases.CONCLUSIONS
Future advances in HSCT will likely require the
introduction of novel agents from various therapeutic
categories that can be added to current standard-of-
care regimens. As described above, based on promising
early-phase clinical results, several such agents now
appear ready for prospective randomized evaluation
inHSCT, the gold standard for determining their util-
ity. The coming decade offers the possibility of major
advances in HSCT.ACKNOWLEDGMENTS
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